Use of cardiotonic therapy in the management of infants with PPHN.
The author describes the rational use of cardiotonic agents in those infants with PPHN in whom myocardial dysfunction and/or extremely abnormal systemic vascular resistance have been completely documented.
D000818:Animals; D000831:Animals, Newborn; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004070:Digitalis; D004077:Digoxin / Q000008:administration & dosage / Q000009:adverse effects; D004280:Dobutamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004285:Dogs; D004298:Dopamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007231:Infant, Newborn; D007545:Isoproterenol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010547:Persistent Fetal Circulation Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D010946:Plants, Medicinal; D010947:Plants, Toxic; D012756:Sheep; D013552:Swine
D002316:Cardiotonic Agents; D004280:Dobutamine; D004077:Digoxin; D007545:Isoproterenol; D004298:Dopamine